We leverage and complement our own research and development skills by working closely with a wide network of partners and collaborators. Together, we can create a world‑class team that is able to contribute innovative solutions to the market to help patients.
At Almirall, we value strategic collaborations with a wide range of partners to advance dermatology research and development.
By collaborating with companies operating at the cutting edge of biotechnology and pharmaceuticals, we maximize the value and time needed to bring solutions to patients.
We actively engage in co-funded projects with academic institutions and industry partners, pooling resources to support the development of innovative dermatology treatments. These joint ventures allow us to tackle the most pressing challenges in dermatology research, bringing together diverse expertise to deliver effective solutions.
Access to bold innovation through partnerships with leading academia research groups and key industrial partners.
Access to bold innovation through partnerships with leading academia research groups and key industrial partners.
Remain up to date on the latest developments in our R&D collaborations. Here, you’ll find news on new partnerships, breakthroughs in dermatology research, and the impact of our collective efforts in advancing medical treatments.
1/3
Today, we announced a strategic research collaboration and licensing agreement with Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma. Through this collaboration, we will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
Almirall has entered a collaboration and licensing agreement with Chinese company CrystalO for the discovery and development of novel small molecules in medical dermatology.
Almirall has entered a collaboration and licensing agreement with Chinese company CrystalO for the discovery and development of novel small molecules in medical dermatology.
Today, we announced a strategic research collaboration and licensing agreement with Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma. Through this collaboration, we will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
We are strengthening our global innovation ecosystem with the opening of new offices in Shanghai, located in the Jing’an district.